Serological prevalence of human parvovirus B19 in diseases or disorders related to different human body systems

被引:5
作者
Aktas, Osman [1 ]
Aydin, Hakan [2 ]
Uslu, Hakan [1 ]
机构
[1] Ataturk Univ, Fac Med, Dept Med Microbiol, Erzurum, Turkey
[2] Ataturk Univ, Fac Vet Med, Dept Virol, Erzurum, Turkey
关键词
Human parvovirus B19; seroprevalence; quantitative enzyme immunoassays; human body system diseases; ICD-10; INFECTION; SEROPREVALENCE; ANTIBODIES; CHILDREN; ANEMIA; WOMEN; AGE;
D O I
10.3906/sag-1409-79
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Human parvovirus B19 is a pathogen that affects different parts of the body. We planned this study because of the lack of data on B19 seroprevalence based on different body-system diseases. Materials and methods: The prevalence of parvovirus B19 antibodies was investigated retrospectively in 1239 patients by review of medical records from 2009-2012, according to their diseases classified under general titles in compliance with the International Classification of Diseases (ICD-10). Parvovirus B19-specific antibodies were detected by quantitative enzyme immunoassays. Results: The positivity rate was 27.8% for only IgG, 8.5% for only IgM, and 2.6% for both IgG and IgM. The highest positivity for IgG alone was found in musculoskeletal system and connective tissue diseases (55.9%), while the highest positivity for IgM was found in neoplasms (16.4%). The highest positivity for IgG was seen in rheumatoid arthritis (72.2%) and pregnancy (52.6%), and the highest positivity for total IgM was found in upper respiratory tract disease (21.0%) and hepatic failure (17.1%). Conclusions: Parvovirus B19 seroprevalence was relatively low in northeastern Anatolia compared to most serological studies conducted in other regions. We think that this study has provided the first wide-ranging information on the seroprevalence of B19 in diseases and disorders of the major human body systems.
引用
收藏
页码:368 / 373
页数:6
相关论文
共 26 条
[1]  
[Anonymous], POSTGRAD OBSTET GYNE
[2]  
[Anonymous], TURK MIKROBIYOL CEM
[3]  
[Anonymous], TURKIYE KLINIKLERI J
[4]  
[Anonymous], JOPP DERG
[5]  
Colak D, 1998, KLIMIK J, V11, P61
[6]  
Dagi HT, 2010, MIKROBIYOL BUL, V44, P467
[7]   Neurologic Manifestations Associated with Parvovirus B19 Infection [J].
Douvoyiannis, Miltiadis ;
Litman, Nathan ;
Goldman, David L. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (12) :1713-1723
[8]  
Florea AV, 2007, ARCH PATHOL LAB MED, V131, P799
[9]  
Ghazi HO, 2007, J FAM COMMUNITY MED, V14, P15
[10]   Human parvovirus B19 [J].
Heegaard, ED ;
Brown, KE .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (03) :485-+